Aardvark Therapeutics Appoints David Zhang to Board of Directors
News related to:Aardvark Therapeutics, Inc · 1 min read
SAN DIEGO, Oct. 08, 2026 /CourierPR/ -- Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced the appointment of David Zhang, Ph.D., MBA, to its Board of Directors, effective October 7, 2026. Dr. Zhang brings more than 25 years of experience in clinical strategy, biostatistics, and regulatory submissions from companies such as Abivax, Alumis, MyoKardia, and Genentech/Roche.
Dr. Zhang's extensive background includes leading the biometrics team through positive topline readouts of two pivotal Phase 3 trials of obefazimod in ulcerative colitis at Abivax. From 2021 to 2024, he served as Senior Vice President, Biometrics and Data Management at Alumis Inc., where he played a crucial role in building the biometrics and data management functions, served as interim Chief Information Officer, and helped the company progress through its initial public offering. Prior to this, Dr. Zhang was Vice President, Head of Biometrics, Data Science, and Digital Health at MyoKardia, Inc., where he oversaw the pivotal trial design, readout, and New Drug Application (NDA) submission for CAMZYOS® (mavacamten) for treating obstructive hypertrophic cardiomyopathy. His earlier career saw him holding biometrics and strategic innovation leadership roles at Roche Sequencing Solutions and Genentech/Roche over a 15-year period, and statistician roles at Eli Lilly and Company and Abbott Laboratories.
Dr. Zhang currently serves as Chief Strategy Officer of Abivax S.A., a clinical-stage biotechnology company focused on therapeutics for chronic inflammatory diseases, where he is a member of the Executive Committee and has overseen biometrics, regulatory affairs, quality assurance, and health economics and outcomes research.
In a forward-looking statement, Aardvark noted that Dr. Zhang's contributions will be critical as the company faces important decisions for its lead product, ARD-101. The company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 11, 2026, highlighted the importance of regulatory and strategic guidance as Aardvark moves forward with its clinical programs.